Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORESEE
NCT05430802Phase 2Active, not recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Started Jan 2023; status: active, not recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05430802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430802.